
Getting your Trinity Audio player ready...
|
The Food and Drug Administration recently announced it will loosen the rules to allow importation of a non-approved cancer drug from China. Ironically, this dangerous move is supposed to make up for a scarcity of critical medicines the Biden Administration itself helped to create.
There’s no question that prescription drug shortages are a serious problem. In the last five years, the United States has gone from 202 medicines in short supply to 301, a 49% increase. But instead of letting in a flood of risky imports, the federal government should consider reversing some of its own policies.
The administration has exacerbated drug shortages through both action and inaction. The chief cause of our current crisis is consolidation among the drug-industry middlemen known as Pharmacy Benefit Managers, or PBMs, which purchase drugs to pass on to insurers. Three giant PBMs control nearly 80% of the U.S. market for prescription medicine.
With their outsized buying power, PBMs drive down drug manufacturers’ margins, especially for those that make lower-cost generic medicines. As a result, manufacturers are exiting specific drug markets or shutting down, contributing to shortages. The murky and unregulated PBM industry is in desperate need of more oversight, but so far, the federal government has provided none.
Meanwhile, the Biden administration has guaranteed more future shortages by signing last year’s Inflation Reduction Act, which imposes price controls on brand-name drugs sold through Medicare. The law is sure to diminish drug innovation and availability.
Here’s why.
Currently, brand-name drugs are significantly more expensive than generic ones. Yet only 10% of prescriptions filled in the United States are for brand-name drugs.
The other 90% percent are for generics, but because generic prices are so much lower, they only account for 20% of consumer drug costs.
Manufacturers can see the writing on the wall. Generic drugs bring in significantly lower margins for their makers, who are able to stay in business by selling in volume. But if the IRA forces brand-name prices down to generic levels, it will squeeze generic manufacturers, possibly forcing them out of the marketplace altogether.
Fewer suppliers will leave us with less competition and, therefore, higher prices — and even more supply-chain disruptions and shortages.
It’s no wonder that the administration wants a solution. Right now, the United States lacks a sufficient supply of two dozen chemotherapy drugs, many of which have no adequate alternative. Even “good” substitutes can be impractical, thanks to harsher side effects or different dosing regimens.
Consider cisplatin and carboplatin, two common cancer therapies. According to a recent survey, a whopping 93% of U.S. cancer centers don’t have enough carboplatin to meet their patients’ needs, while 70% face a shortage of cisplatin. And substituting cisplatin for carboplatin can be dangerous — involving greater deterioration of kidney function.
Ironically, this particular shortage largely derives from the drugs’ appealing list-prices. Marked at just $15 and $25 a vial, respectively, cisplatin and carboplatin don’t attract a lot of pharmaceutical investment. So when one manufacturer goes down, backup plans — like the drugs themselves — remain in short supply.
As a result, it’s no surprise to find doctors rationing treatments for bladder, breast, and ovarian cancer. Experts calculate these restrictions are endangering more than 100,000 cancer patients.
Yet turning to China as a supplier is dangerous. The U.S. Food and Drug Administration is the global gold standard in drug approval, which is why Americans can have such high confidence in the drugs they purchase. They know that the label on the package matches the contents and that the product inside is safe and effective.
That’s not necessarily true in the rest of the world. According to the World Health Organization, counterfeit drugs cause an estimated one million deaths a year. In developing countries, roughly 10% of drugs sold are substandard or counterfeit.
But counterfeit drugs also make their way into wealthy nations. In one Canadian operation targeting illicit global pharmaceutical networks, border guards found that 87% of 3,600 packages they inspected contained counterfeit or unlicensed health products. And when pharmaceutical companies banded together to track fake versions of their products, they found 13,439 incidents over 10 years. In 2018, for example, Pfizer identified 95 fake “Pfizer” products in 113 countries.
By impeding domestic drug innovation and promoting foreign imports, the Biden administration is undermining drug security. Under the new policy, the FDA is allowing imports of the unapproved Chinese cancer treatment cisplatin so quickly that the labels will still be in Chinese. This suggests a slapdash process that counterfeiters could easily exploit.
Instead of turning to unreliable foreign sources, the administration would do better to undo its own misguided policies that have contributed to shortages in the first place. American cancer patients deserve a safe and secure supply of treatments.
Peter J. Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest. He also serves as a Visiting Professor at University of Paris School of Medicine.
Globalism is the real problem, if local businesses are producing products for local people then the audit trail is easier to monitor.
The dumb regulators have forced every business to put stupid labels on boxes and inside them too with reams of paper that nobody actually reads. That in itself makes identifying fake products much more difficult.
Plus China is producing fake products constantly, they get through the customs process by putting the fake product into an outer box that appears to be something different.
The regulators are not helping here and neither are the globalists in the World pHarma Organisation.
Oh, I forgot to mention that the forced vaccination program probably had an impact too. But we can’t mention convid anymore can we?
What is covid? Did I miss something?
The pharmacy benefit managers are impeding trade and should be sanctioned under monopoly legislation. Trade isn’t free if any company is setting prices or operating in illegal or substandard ways.
OMG, this smacks of Joe being bought off for this favor for China.
China could own us in a month. All they’d have to do is cut off imports of critical and not so critical consumer products. Think of all the market shelves that would go empty in a matter of days and the ensuing pandemonium. All the big box stores would close, Amazon would be reduced to books and audio files and, yes, the pharmacies wouldn’t even have knee braces or birthday cards. They (China) are expanding their markets and influence around the world and may take a short-term economic hit but the objective will be met, the collapse of America. Our only option will be to bomb them out of existence but that still leaves us in the same place. I know I sound paranoid but this is one possible outcome of depending on a major political foe to supply us with so much of our vital needs. Globalism sounds great to those making all the money but it doesn’t mean everyone sees it the same. We’d better get back to being a production economy, as opposed to a “service” economy while we still can.
This country messed up when it transferred so many things to be made that are of vital importance to Americans. Jobs, automobiles, pharmaceuticals, clothing, parts…..anything that Americans need we are now dependent upon other countries for. The elites are controlling our future.